Forum Financial Management LP lessened its holdings in shares of Centene Co. (NYSE:CNC – Free Report) by 6.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 8,124 shares of the company’s stock after selling 514 shares during the period. Forum Financial Management LP’s holdings in Centene were worth $612,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in CNC. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Centene by 18.7% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 624,944 shares of the company’s stock valued at $49,046,000 after buying an additional 98,298 shares during the period. GSA Capital Partners LLP raised its position in Centene by 435.0% in the 1st quarter. GSA Capital Partners LLP now owns 20,052 shares of the company’s stock valued at $1,574,000 after buying an additional 16,304 shares during the last quarter. Diversified Trust Co raised its position in Centene by 35.8% in the 2nd quarter. Diversified Trust Co now owns 28,009 shares of the company’s stock valued at $1,857,000 after buying an additional 7,385 shares during the last quarter. Bessemer Group Inc. raised its position in Centene by 189.6% in the 1st quarter. Bessemer Group Inc. now owns 24,162 shares of the company’s stock valued at $1,895,000 after buying an additional 15,819 shares during the last quarter. Finally, Comerica Bank raised its position in Centene by 7.3% in the 1st quarter. Comerica Bank now owns 118,597 shares of the company’s stock valued at $9,307,000 after buying an additional 8,103 shares during the last quarter. Institutional investors own 93.63% of the company’s stock.
Analyst Upgrades and Downgrades
CNC has been the topic of a number of recent research reports. Robert W. Baird dropped their target price on Centene from $83.00 to $66.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein reduced their target price on Centene from $96.00 to $88.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Stephens reiterated an “equal weight” rating and set a $78.00 target price on shares of Centene in a research note on Monday, August 5th. Truist Financial reduced their target price on Centene from $92.00 to $89.00 and set a “buy” rating for the company in a research note on Monday, July 15th. Finally, JPMorgan Chase & Co. reduced their target price on Centene from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Centene has a consensus rating of “Moderate Buy” and an average target price of $83.92.
Centene Price Performance
Shares of NYSE CNC opened at $63.82 on Tuesday. The stock has a market capitalization of $32.22 billion, a PE ratio of 11.08, a P/E/G ratio of 0.85 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.10 and a quick ratio of 1.17. The business has a fifty day moving average price of $70.97 and a two-hundred day moving average price of $71.89. Centene Co. has a fifty-two week low of $59.77 and a fifty-two week high of $81.42.
Centene Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Featured Articles
- Five stocks we like better than Centene
- Using the MarketBeat Stock Split Calculator
- Intel: Is Now the Time to Be Brave?
- How to invest in marijuana stocks in 7 steps
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Where Do I Find 52-Week Highs and Lows?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Co. (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.